Octagon Capital Advisors LP
Source: SEC Form 13F · as of Mar 2026Octagon Capital Advisors LP holds 18 biotech & pharma companies tracked by BioSniper, totaling $546.6M in value as of Mar 2026 (SEC Form 13F).
Companies held
18
Total value held
$546.6M
| Company | Shares | Value |
|---|---|---|
| COGTCogent Biosciences, Inc. | 2,350,000 | $90.5M |
| ABVXAbivax SA | 677,000 | $75.4M |
| ALMSALUMIS INC. | 2,830,700 | $62.4M |
| TSHATaysha Gene Therapies, Inc. | 8,859,911 | $39.6M |
| KYMRKymera Therapeutics, Inc. | 425,000 | $35.4M |
| MIRMMirum Pharmaceuticals, Inc. | 338,900 | $31.3M |
| CNTACentessa Pharmaceuticals plc | 750,000 | $29.8M |
| KALVKalVista Pharmaceuticals, Inc. | 1,450,000 | $29.2M |
| XENEXenon Pharmaceuticals Inc. | 490,000 | $28.5M |
| TERNTerns Pharmaceuticals, Inc. | 530,000 | $27.9M |
| OCULOCULAR THERAPEUTIX, INC | 3,166,600 | $26.8M |
| TRVITrevi Therapeutics, Inc. | 1,485,000 | $17.7M |
| IRONDisc Medicine, Inc. | 270,000 | $17.3M |
| AKTSAktis Oncology Inc. | 960,847 | $17.2M |
| BBOTBridgeBio Oncology Therapeutics, Inc. | 719,000 | $6.4M |
| PHVSPharvaris N.V. | 165,000 | $4.7M |
| CATXPerspective Therapeutics, Inc. | 791,555 | $3.3M |
| EVMNEvommune, Inc. | 143,472 | $3.3M |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.